Woolson Daniel 4

What Happened

• Daniel Woolson, Vice President and GM—Infusion Capital at ICU Medical (ICUI), had 2,924 performance-based restricted stock units (PRSU) convert to common shares on March 15, 2026. There was no exercise price for the PRSUs.
• To cover tax withholding, 1,295 of those shares were surrendered/withheld at $125.85 per share, representing $162,976. After withholding, Woolson received a net of 1,629 shares (2,924 gross − 1,295 withheld).
• This is receipt/vesting of an award (not an open-market purchase or voluntary sale); the share withholding for taxes is a routine disposition to satisfy tax obligations.

Key Details

• Transaction date: March 15, 2026 (reported on Form 4 filed March 16, 2026 — timely filing).
• Converted/received: 2,924 shares (PRSU conversion; $0 exercise price). Tax withholding/disposed: 1,295 shares at $125.85/share = $162,976.
• Net new shares retained by insider: 1,629 shares.
• Footnotes: These were performance-based restricted stock units (PRSU) granted May 17, 2023. PRSUs have no purchase/exercise price and vest subject to performance and time-based criteria, vesting on March 15 in the first, second, and third year after grant.
• Filing timeliness: appears timely (transaction 3/15/2026, Form 4 filed 3/16/2026).
• Form codes: M = conversion/exercise of derivative (PRSU → shares); F = shares withheld/used to satisfy tax withholding.

Context

• This was a vesting/settlement of performance-based RSUs with a cashless-type withholding to cover taxes, a common administrative step that doesn't necessarily signal insider sentiment.
• Net share increase (1,629 shares) is the actionable change in Woolson’s direct holdings from this event. The filing does not state total shares owned after the transaction; refer to the full Form 4 for ownership totals.